What somatic and germline testing is recommended for me
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Understanding Somatic and Germline Testing for Cancer
I appreciate your question, but I need to be direct with you: I cannot recommend specific testing for your individual situation because you haven't shared your cancer type or stage, and testing recommendations are highly personalized based on your specific diagnosis.
However, I can explain what these tests are and how doctors think about them—which will help you have a better conversation with your oncology team.
What These Tests Measure
Somatic Testing examines mutations (genetic changes) that occur only in your tumor cells—not in your normal cells. These changes happened during your lifetime and are not inherited. Somatic mutations help doctors understand:
- What's driving your specific cancer
- Which targeted therapies might work
- How your tumor might respond to immunotherapy
Germline Testing looks for inherited genetic mutations present in all your cells (including normal ones) that you were born with. These tests help identify:
- Whether you have a hereditary cancer syndrome
- Your lifetime cancer risk
- Whether family members should be screened
- Whether certain preventive measures apply to you
How Doctors Decide What Testing to Order
According to the CancerPatientLab webinars on precision oncology, the clinical decision-making process involves:
- Understanding your tumor biology - Doctors use whole exome sequencing (DNA analysis) and whole transcriptome sequencing (RNA analysis) to identify actionable biomarkers
- Evaluating the tumor microenvironment - Understanding immune cell infiltration and spatial organization to predict immunotherapy response
- Considering clinical utility - As emphasized in the webinars, "the clinical utility for some of these tests is not there yet" - meaning doctors focus on tests that actually change treatment decisions
Questions to Ask Your Oncology Team
Since testing recommendations depend entirely on your specific cancer type and stage, ask your doctor:
-
"What somatic mutations are most common in my type of cancer, and which ones have FDA-approved targeted treatments?"
-
"Based on my tumor characteristics, which somatic tests do you recommend, and how will the results change my treatment options?"
-
"Does my cancer type or family history suggest I should have germline testing? If so, which genes are relevant?"
-
"If germline testing is recommended, what are the implications for my family members?"
-
"Are there any emerging biomarkers or tests you're considering that might provide additional insights into my specific tumor?"
Why This Matters
The webinars highlight an important principle: testing should have clinical utility—meaning the results actually inform treatment decisions. Your oncologist will determine which tests meet this standard for your particular situation.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with diagnosis for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2